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Implications of genetic variation 
of common Drug Metabolizing 
enzymes and ABC transporters 
among the pakistani population
Nasir Ali Afsar1, Henrike Bruckmueller2, Anneke Nina Werk2,3, Muhammad Kashif Nisar1,6, 
H. R. Ahmad4,5 & Ingolf Cascorbi  2
Genetic polymorphism of drug metabolizing enzymes and transporters may influence drug 
response. the frequency varies substantially between ethnicities thus having implications on 
appropriate selection and dosage of various drugs in different populations. The distribution of genetic 
polymorphisms in healthy Pakistanis has so far not been described. In this study, 155 healthy adults 
(98 females) were included from all districts of Karachi. DNA was extracted from saliva and genotyped 
for relevant sNVs in CYP1A1, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 as well as 
ALDH3A1, GSTA1, ABCB1 and ABCC2. About 64% of the participants were born to parents who were 
unrelated to each other. there was generally a higher prevalence (p < 0.05) of variant alleles of CYP450 
1A2, 2B6, 2C19, 3A5, ALDH3A1, GSTM1 as well as ABCB1 and ABCC2 in this study cohort than in other 
ethnicities reported in the HapMap database. In contrast, the prevalence of variant alleles was lower in 
GSTA1. Therefore, in the Pakistani population sample from Karachi a significantly different prevalence 
of variant drug metabolizing enzymes and ABC transporters was observed as compared to other 
ethnicities, which could have putative clinical consequences on drug efficacy and safety.
The concept of choosing the right medicine for right person is not new. However, pharmacogenomic research has 
enabled us to predict an adverse outcome of administering a medication that would formerly have been judged to 
be generally safe and effective1. Due the initiative of the Clinical Pharmacogenetics Implementation Network and 
others2, many drugs in the USA are now dispensed with FDA advised pharmacogenetic warning labels. A detailed 
list of pharmacogenetic markers is available online at the FDA website (www.fda.gov/Drugs/ScienceResearch/
ucm572698.htm). Drug regulatory agencies like the European EMA are following the lead. However, such data 
stems mainly from the West, which may not be applicable to other parts of the world.
Genetic variability of drug metabolizing enzymes and drug transporters has been associated with interindi-
vidual differences in pharmacokinetics and pharmacodynamics. Such differences may result in variation in drug 
efficacy, safety and treatment outcomes in a number of frequently prescribed drugs3. A notable example is that of 
pharmacogenetic peculiarities of Ashkenazi Jewish population who are reported to have important therapeutic 
implications, such as VKORC1 gene polymorphism necessitating warfarin dose adjustment4. Hence, interindivid-
ual genetic differences within but also between various ethnic groups are considered to be an important contrib-
utory factor to the variability of drug responses5. In this study, we characterized single nucleotide variants (SNVs) 
of select phase I enzymes (CYPs and ALDHs), phase II enzymes (GSTs, UGTs, TPMPTs and NATs) and trans-
porters involved in drug metabolism in a population of 155 Karachiites in Pakistan, because no such studies are 
reported for this population. Further, we compared the variant allele frequency with allele frequencies reported 
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for major ethnic groups in HapMap database and reported the differences between our population and each of 
those representative groups in HapMap.
It is estimated that 75–80% of prescribed drugs are metabolized by oxidizing phase I cytochrome P450 
enzymes such as CYP3A4 and 5, CYP2D6, CYP2C19 or CYP2C9, with CYP3A4/5 metabolizing more than half of 
currently prescribed drugs6. In addition, phase II enzymes catalyze the conjugation of xenobiotic metabolites with 
various hydrophilic molecules to render them less toxic and more polar, thus favouring their excretion from the 
body. Such reactions are catalyzed by different enzyme groups, such as GSTs (glutathione S-transferases), UGTs 
(UDP-glucuronosyl transferases), TPMTs (thiopurine S-methyl transferases), NATs (N-acetyl transferases)7. 
GSTs also support detoxification reactions8 and play an important role in preventing oxidative stress9.
Additionally, ALDHs (aldehyde dehydrogenases) are phase I xenobiotic metabolizing enzymes which have 
diverse functions, such as neutralization of toxic aldehydes during lipid peroxidation10, coenzyme Q synthesis11, 
prevention of tobacco smoke-induced respiratory epithelial cytotoxicity12, metabolism of cyclophosphamide8 
and ethanol13 among other functions. Thus, altered ALDH function could predispose individuals to numerous 
medical conditions such as atherosclerosis, dementia, infertility, cancers. This becomes further complicated if the 
biological role shows a gene-dose effect, as we previously reported for ALDH3A18.
ATP binding cassette (ABC) transporters are a group of membrane transporters, which transport many xeno-
biotics, including drugs, in and out of various cells. In fact, some of them were called multi-drug resistance pro-
teins because of this role. Of notable interest are ABCB1 and ABCC2 transporters. Their substrates include many 
drugs, including anticancer drugs, HIV protease inhibitors, antibiotics, beta blockers, statins, anticonvulsants, 
opiates14.
As outlined above, ethnic differences exist in the prevalence of genetic variants of the enzymes and transport-
ers15. Hence, genetic characterization of patients may prove valuable in predicting therapeutic outcomes16–18. 
We reported previously19 that significant differences exist in the frequencies of polymorphic genes involved in 
metabolism and cellular transport of breast cancer chemotherapy among breast cancer patients from Karachi, as 
compared to some ethnic groups reported in HapMap database (https://www.ncbi.nlm.nih.gov/snp). However, 
that study was limited because of the small sample size used and the absence of data from a healthy population.
To the best of our knowledge, there is no comprehensive study on this topic involving South Asia and adjoin-
ing regions. Hence, we designed this study to explore the genotype profiles among healthy adults from different 
ethnicities living in Karachi, allowing us to compare them with those reported for other major ethnic groups in 
the HapMap database.
Results
Table 1 shows the baseline characteristics of the study population. A total of 155 healthy Pakistani adults (98 
females and 57 males) with a median age of 19 years (range: 18–70 years) were included in this study. Participants 
were from all districts of Karachi and belonged to various major ethnic groups within Pakistan. Ethnicity was 
classified according to their mother tongue, including Balochi, Gujrati, Pashtun, Punjabi, Seraiki, Sindhi, and 
other minor groups. As expected, the local Urdu-speaking community with heterogeneous Indian ancestry, col-
lectively described as Muhajir (Arabic/Urdu; immigrants) featured most in our population. Since consanguineous 
marriages are common in Pakistan20, we sought information regarding this fact. Most individuals declared that 
Participant Characteristics
Participant Mother Father
N % n % n %
Gender
Female: 98 63.2
Male: 57 36.8
Ethnicity
Urdu Speaking: 92 59.4 101 65.2 96 61.9
Sindhi: 10 6.5 11 7.1 12 7.7
Gujrati: 9 5.8 11 7.1 13 8.4
Punjabi: 8 5.2 11 7.1 11 7.1
Pashtun: 5 3.2 6 3.9 5 3.2
Seraiki: 2 1.3 2 1.3 2 1.3
Others: 6 3.9 6 3.9 7 4.5
Mixed lineage: 18 11.6
Not declared 5 3.2 7 4.5 9 5.8
Consanguinity
No: 99 63.9
Yes: 55 35.5
District
East: 71 45.8
Central: 33 21.3
South: 28 18.1
Korangi: 9 5.8
Malir: 8 5.2
West: 3 1.9
Table 1. Baseline characteristics of study participants.
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their parents were not related to each other. Some of the participants, labelled as ‘mixed lineage’ had grandparents 
from different ethnicities.
Table 2 shows the frequency distribution of SNVs and genotypes. Genotypes were in Hardy-Weinberg equi-
librium. Some of the samples could not be genotyped completely, apparently due to low DNA quantity or quality. 
Haplotype and diplotype analyses were carried out where applicable. Table 2 shows that in our population the 
percent frequency of wild type genotype was as follows:
 (a) Phase I enzymes: CYP1A1 42% (heterozygous 46%; homozygous variant 12%), CYP2B6 20% (heterozy-
gous 54%; homozygous variant 26%), CYP2C9 71% (heterozygous 26%), CYP2C19 27% (heterozygous 
48%; homozygous variant 25%), CYP2D6 extensive metabolizers 74% (25% intermediate metabolizers, 
1% poor metabolizers), CYP3A4 98% (heterozygous 2%), CYP3A5 1% (heterozygous 38%, homozygous 
variant 61%), ALDH3A1 8% (heterozygous 50%, homozygous variant 42%).
 (b) Phase II enzymes: GSTA1 49% (heterozygous 41%, homozygous variant 10%), GSTM1 null 59%.
 (c) ABC Transporters: ABCB1 wildtype haplotype 10%, ABCC2 wildtype haplotype 50%
Table 3 and Fig. 1 show variant allele frequencies. This study compared Pakistani population with major global 
ethnic groups (African of Yoruba Nigerian ancestry, Caucasian of Northern and Western European ancestry, 
Chinese of Han ancestry) as well as a subset from the neighbouring area of India (Gujrati Indians in Houston, 
Texas), all taken from the HapMap database. Variant allele frequencies were compared using Chi-square or 
Fischer exact tests. The results show that as compared to ethnicities in the HapMap database there were significant 
differences in prevalence of variant alleles of (a) ALDH3A1, (b) CYP1A1*2A, CYP2B6*4, CYP2B6*6, CYP2C19*2, 
CYP3A5*3, (c) GSTA1, and (d) ABCB1 2677G > T/A and ABCC2 1249G > A in our population. GSTM1 null gen-
otype was found higher than in other reported ethnicities. CYP2D6*3 was absent in our study sample. All other 
SNVs showed intermediate or similar prevalence of variant alleles as compared to other ethnicities.
Discussion
This study is the first comprehensive pharmacogenetic report from Pakistan. Previously we had shown that SNV 
prevalence of a select group of Phase-I as well as Phase-II drug metabolizing enzymes and ABC transporters 
in a breast cancer population sample had significant differences as compared to various ethnicities in HapMap 
database19. In this study also we identified several important differences between allele and genotype frequencies 
compared to other populations. Interestingly, the differences were similar to those reported previously for breast 
cancer population19, suggesting that real differences might exist. It is important to understand the implications of 
such differences in this population as compared to others as a first step to precision medicine globally. For exam-
ple, an altered gene function can lead to unfavourable therapeutic outcome(s) in acute care or chronic manage-
ment of various disorders. A few recent examples where gene variant necessitate adjusted dosing of a drug include 
that of clopidogrel in case of CYP2C19 SNVs21, warfarin in case of CYP2C9 or VKORC1 SNVs22 and tamoxifen 
in case of CYP2D6 SNVs23.
This study has many advantages. Pakistan is a populous multi-ethnic country with more than 200 million 
inhabitants. We included people from various major ethnic groups including Urdu-speaking, Balochi, Gujrati, 
Pashtun, Punjabi, Seraiki and Sindhi. The presence of a substantial proportion of Urdu-speaking population 
enabled us to extend the relevance of our results to neighbouring India which has a population over 1300 million. 
Overall their relevance could be extended to approximately 20–25% of the World’s population, which is histor-
ically underrepresented in pharmacogenomic studies. Hence, these results provide an important window to a 
largely unstudied population. Despite this, there are some limitations of our study. Approximately one third of our 
study population represented an inbred cohort due to consanguineous marriages, a widespread practice in this 
region. Further, our study cohort did not have substantial numbers of other Pakistani ethnic groups, like Baloch, 
Pashtun, Punjabi and Sindhi for sub-group analysis and robust conclusions regarding these ethnic groups. Hence, 
we recommend replicating the study to target these groups across the country and region.
The following section discusses in depth the implications of various significant observations in our study 
sample, comparing it with other ethnicities documented in the HapMap database, including African, Caucasian, 
Chinese and Gujrati. For further research and analysis, a web-based detailed account regarding substrates, induc-
ers and inhibitors of various drug metabolizing enzymes, and updated clinical application of pharmacogenetics 
(CPIC guidelines) can be found at https://www.pharmgkb.org/, http://bioinformatics.charite.de/transformer/. 
and https://cpicpgx.org/guidelines/.
CYP1A1. Cytochrome P450 1A1 metabolizes xenobiotics such as polycyclic aromatic hydrocarbons (PAHs) 
found in tobacco smoke, atmospheric pollutants and industrial waste and generates carcinogens from several sub-
strates24. Hence, CYP1A1 is considered a link between environment-gene interaction in the etiology of various 
cancers such as head and neck cancers among smokers25. Our sample shows a higher prevalence of variant alleles 
(58% of diplotypes carried at least one variant allele) as compared to Caucasians and could potentially confer an 
elevated disease risk although this would need further validation. The difference in prevalence of SNVs could 
also have an impact on therapeutic outcome of drugs that may be favourable such as in case of antineoplastic 
docetaxel26, or first-line antiepileptics27, but unfavourable for antiemetic granisetron28.
CYP2B6. Our results show a significantly higher prevalence of variant alleles CYP2B6*4 (48%) and CYP2B6*6 
(36%) genotypes as compared to other ethnicities reported in HapMap database. Both alleles are associated with 
lower CYP2B6 activity leading to pharmacogenetic implications with many drugs including the antidepressant 
bupropion29, antiretroviral efavirenz30, anti-tuberculosis rifamycins and ethionamide31, among others. Pakistan 
has a high prevalence of tuberculosis, whereas HIV prevalence is on the rise especially in high-risk groups like 
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Gene rs number SNV
Genotyping 
Success (%)
Minor 
allele (%)
Genotype/
Diplotype
Participants 95% Confidence 
Interval(n) (%)
CYP1A1
rs1799814 g.2452C > A 92.3 1.7 *1/*1 61 42.4 34.29 — 50.43
rs1048943 g.2454A > G 96.1 11.1 *1/*2A 42 29.2 21.74 — 36.59
rs4646903 g.3798 T > C 92.9 32.6 *1/*2B 19 13.2 7.67 — 18.72
*1/*2C 1 0.7 0.00 — 2.05
*1/*4 4 2.8 0.09 — 5.46
*2A/*2A 6 4.2 0.90 — 7.43
*2A/*2B 7 4.9 1.35 — 8.37
*2A/*4 1 0.7 0.00 — 2.05
*2B/*2B 3 2.1 0.00 — 4.42
CYP2B6
rs3745274 g.516G > T 94.8 36.1 *1/*1 29 20.4 13.79 — 27.05
rs2279343 g.785A > G 80.0 48.0 *1/*4 10 7.0 2.83 — 11.25
rs3211371 g.1459C > T 79.4 8.1 *1/*5 12 8.5 3.88 — 13.03
*1/*6 51 35.9 28.02 — 43.81
*1/*9 3 2.1 0.00 — 4.48
*4/*4 4 2.8 0.10 — 5.54
*4/*6 8 5.6 1.84 — 9.43
*4/*7 1 0.7 0.00 — 2.08
*4/*33 2 1.4 0.00 — 3.35
*5/*6 4 2.8 0.10 — 5.54
*6/*6 17 12.0 6.63 — 17.31
*6/*7 1 0.7 −0.67 — 2.08
CYP2C9
rs1799853 c.430C > T 94.8 6.8 *1/*1 108 70.6 63.37 — 77.81
rs1057910 c.1075A > C 97.4 9.9 *1/*2 16 10.5 5.61 — 15.31
*1/*3 24 15.7 9.92 — 21.45
*2/*3 0 0.0 — — —
*2/*2 4 2.6 0.09 — 5.14
*3/*3 1 0.7 0.00 — 1.93
CYP2C19
rs4244285 c.681G > A 100 31.0 *1/*1 42 27.1 20.10 — 34.09
rs12248560 g.-806C > T 98.1 18.1 *1/*2 46 29.7 22.49 — 36.87
*1/*17 29 18.7 12.57 — 24.85
*2/*2 15 9.7 5.02 — 14.33
*2/*17 20 12.9 7.63 — 18.18
*17/*17 3 1.9 0.00 — 4.10
CYP2D6
rs1065852 g.100C > T 78.1 17.8 *1/*1 (EM) 56 73.7 63.78 — 83.58
rs5030655 g.1707delT 49.7 0.6 *1/*10 (IM) 3 3.9 −0.43 — 8.33
rs3892097 g.1846C > T 49.7 11.0 *1/*4 (IM) 14 18.4 9.71 — 27.14
rs35742686 g.2549delA 96.1 0.0 *1/*6 (IM) 1 1.3 0.00 — 3.88
rs5030656 g.2615-g.2617delAAG 90.3 0.4 *1/*9 (IM) 1 1.3 0.00 — 3.88
*4/*10 (PM) 1 1.3 0.00 — 3.88
CYP3A4
rs35599367 g.15389C > T 100 1.0 *1/*1 152 98.1 95.91 — 100.21
*1/*22 3 1.9 0.00 — 4.09
*22/*22 0 - — —
CYP3A5
rs776746 g.6986G > A 78.7 20.1 *1/*1 1 0.8 0.00 — 2.40
*1/*3 47 38.5 29.89 — 47.15
*3/*3 74 60.7 51.99 — 69.33
ALDH3A1
rs2228100 c.985G > C 95.5 33.1 C/C 12 8.1 3.71 — 12.51
C/G 74 50.0 41.94 — 58.06
G/G 62 41.9 33.94 — 49.84
GSTA1
rs3957357 g.−69C > T 99.4 30.5 *A/*A (CC/GG) 75 48.7 40.81 — 56.59
rs3957356 g.-52G > A 99.4 30.5 *A/*B (CG/TA) 64 41.6 33.78 — 49.34
*B/*B (TT/AA) 15 9.7 5.07 — 14.41
GSTM1 *0 (null) 99.4 30.1 *1/*1, *0/*1 60 39.0 31.26 — 46.66
Continued
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sex workers and intravenous drug addicts32. Hence, compromised CYP2B6 function in the population could lead 
to elevated risk of side effects and drug-drug interactions. Further research is needed to evaluate the situation in 
this respect.
Gene rs number SNV
Genotyping 
Success (%)
Minor 
allele (%)
Genotype/
Diplotype
Participants 95% Confidence 
Interval(n) (%)
(Gene Deletion) *0/*0 91 59.1 51.32 — 66.86
ABCB1
rs1128503 g. c.1236C > T 97.4 59.3 C/C 27 17.9 11.77 — 23.99
C/T 68 45.0 37.10 — 52.96
T/T 55 36.4 28.75 — 44.09
rs2032582 c.2677G > T/A 96.8 T: 58.6 G/G 22 16.5 10.23 — 22.85
A: 6.3 G/T 57 42.9 34.45 — 51.27
T/T 54 40.6 32.25 — 48.95
G/A 5 3.8 0.53 — 6.99
T/A 12 9.0 4.15 — 13.89
A/A 1 0.8 −0.72 — 2.22
rs1045642 c.3435C > T 98.7 53.6 C/C 31 20.3 13.89 — 26.63
C/T 80 52.3 44.38 — 60.20
T/T 42 27.5 20.37 — 34.53
*1/*1 
(CGC/CGC) 14 9.6 4.81 — 14.37
*1/*2 (CGC/TT 
(>A)T) 37 25.3 18.28 — 32.40
*2/*2 (TTT/A) 33 22.6 15.82 — 29.38
Mixed 62 42.5 34.44 — 50.48
ABCC2
rs717620 c.-24C > T 98.7 14.6 C/C 113 73.9 66.90 — 80.82
C/T 37 24.2 17.39 — 30.97
T/T 4 2.6 0.09 — 5.13
rs2273697 c.1249G > A 97.4 24.2 G/G 84 55.6 47.71 — 63.55
G/A 61 40.4 32.57 — 48.23
A/A 6 4.0 0.84 — 7.10
rs3740066 c.3972C > T 99.4 37.3 C/C 58 37.7 30.01 — 45.31
C/T 72 46.8 38.87 — 54.63
T/T 20 13.0 7.68 — 18.30
H1 (CGC) 146 50.0 58.11 — 41.89
H2 (CAC) 39 13.4 18.89 — 7.83
H9 (CGT) 43 14.7 20.47 — 8.99
H12 (TGT) 31 10.6 15.61 — 5.63
H13 (CAT) 23 7.9 12.26 — 3.50
H14 (TAC) 9 3.1 5.89 — 0.27
H15 (TAT) 1 0.3 1.28 — −0.60
H1/H1 22 15.1 20.88 — 9.26
H1/H2 32 21.9 28.63 — 15.21
H1/H9 28 19.2 25.57 — 12.79
H1/12 16 11.0 16.04 — 5.88
H1/13 17 11.6 16.83 — 6.45
H1/14 9 6.2 10.07 — 2.25
H2/H2 3 2.1 4.38 — −0.28
H2/H13 1 0.7 2.03 — −0.67
H9/H9 3 2.1 4.38 — −0.28
H9/H12 7 4.8 8.26 — 1.32
H9/H13 1 0.7 2.03 — −0.67
H9/H15 1 0.7 2.03 — −0.67
H12/H12 4 2.7 5.37 — 0.11
H13/H13 2 1.4 3.28 — −0.54
Table 2. Allele and diplotype frequencies of SNVs in drug metabolizing enzymes and ABC transporters 
(n = 155 healthy adults).
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Genotype KHI Sample HapMap Ethnicities Variant Allele % χ² Value p-value
CYP1A1*2 11.07
CHIN 25.6 7.05 0.008
CAUC 3.1 4.83 0.028
GUJ 10.2 0.04 0.84
AFR 0 6.18 0.013
CYP1A1*2A 32.64
CHIN 37.5 0.52 0.47
CAUC 10 15.28 <0.001
GUJ — —
AFR 14.4 9.25 0.002
CYP1A1*4 1.75
CHIN 0 0.89 0.35
CAUC 2.5 0.136 0.71
GUJ — —
AFR 0 0.89 0.35
CYP2B6*4 47.98
CHIN 18.8 19.15 <0.001
CAUC 21.4 15.6 <0.001
GUJ — — —
AFR 45 0.18 0.67
CYP2B6*5 8.13
CHIN — —
CAUC 9.1 0.06 0.81
GUJ — —
AFR 4.2 1.335 0.25
CYP2B6*6 36.05
CHIN 15.1 11.5 0.001
CAUC 27 1.9 0.17
GUJ 41.5 0.63 0.43
AFR 42 0.74 0.39
CYP2C9*2 6.80
CHIN 0 3.6 0.056
CAUC 10.4 0.82 0.36
GUJ — —
AFR 0 3.6 0.056
CYP2C9*3 9.93
CHIN 4.7 2 0.16
CAUC 5.8 1.18 0.28
GUJ 13.1 0.49 0.48
AFR 0 5.49 0.02
CYP2C19*2 30.97
CHIN 25.6 0.71 0.39
CAUC 15.5 6.7 0.01
GUJ — —
AFR 14.4 7.8 0.005
CYP2C19*17 18.09
CHIN 2.2 13.85 <0.001
CAUC 21.7 0.41 0.52
GUJ - -
AFR 27.5 2.5 0.11
CYP2D6*3 0.00
CHIN — —
CAUC — —
GUJ — —
AFR 0 0 1
CYP2D6*4 11.04
CHIN 0.6 9.94 0.002
CAUC 15.4 0.83 0.36
GUJ — —
AFR 9.7 0.1 0.75
CYP2D6*6 0.65
CHIN — —
CAUC 0.5 0.02 0.89
GUJ — —
AFR — —
CYP2D6*9 0.36
CHIN — —
CAUC — —
GUJ — —
AFR 0 0.18 0.67
Continued
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CYP2C9. This enzyme metabolizes many drugs, such as warfarin33, phenytoin34 and non-steroidal 
anti-inflammatory drugs diclofenac and ibuprofen35. Our results show an intermediate prevalence of CYP2C9*2 
genotype in KHI (6.8%) as compared to Caucasian (10.4%) and African (0%) populations in HapMap database. 
However, the CYP2C9*3 genotype is more frequent (9.93%) than in those population groups. Haplotype analysis 
suggests that approximately 30% population has some degree of compromised function of CYP2C9. The potential 
Genotype KHI Sample HapMap Ethnicities Variant Allele % χ² Value p-value
CYP2D6*10 17.77
CHIN 71.7 58.8 <0.001
CAUC 22.5 0.69 0.4
GUJ — —
AFR 11.9 1.36 0.24
CYP3A4*22 0.97
CHIN — —
CAUC 2.5 0.69 0.4
GUJ — —
AFR — —
CYP3A5*3 79.92
CHIN 66.3 4.72 0.03
CAUC 96.4 13 <0.001
GUJ 75.6 0.54 0.46
AFR 15.5 83.2 <0.001
ALDH3A1 985C > G 66.89
CHIN 44.4 10.25 0.001
CAUC 29.2 28.46 <0.001
GUJ — —
AFR 44.1 10.5 0.001
GSTA1 -69C > T and -52G > A 30.52
CHIN 89.5 72.48 <0.001
CAUC 58.4 15.74 <0.001
GUJ 67 26.63 <0.001
AFR 69 29.62 <0.001
GSTM1 30.13
CHIN — —
CAUC 0 20.4 <0.001
GUJ — —
AFR 0 20.4 <0.001
ABCB1 1236C > T or *8 59.33
CHIN 70.9 2.95 0.086
CAUC 45.1 4.1 0.044
GUJ 59.7 0.003 0.96
AFR 12.4 47.88 <0.001
ABCB1 2677G > T/A 64.38
CHIN 61.6 0.17 0.68
CAUC 46.9 6.19 0.01
GUJ 65.3 0.02 0.89
AFR 21 38.46 <0.001
ABCB1 3435C > T 53.59
CHIN 41.7 2.84 0.09
CAUC 57.1 0.25 0.62
GUJ 59.7 0.76 0.38
AFR 11.1 41.26 <0.001
ABCC2 -24C > T 14.61
CHIN 22.1 1.87 0.17
CAUC 18.1 0.44 0.5
GUJ 7.4 2.65 0.1
AFR 3.1 8.21 0.004
ABCC2 3972C > T 24.17
CHIN 26.7 0.17 0.68
CAUC 34.2 2.43 0.12
GUJ — —
AFR 27.5 0.29 0.6
ABCC2 1249G > A 37.33
CHIN 7 26.66 <0.001
CAUC 24.3 3.98 0.046
GUJ 30.7 0.98 0.322
AFR 22.1 5.55 0.02
Table 3. Comparison of variant allele frequency with other ethnic groups. The Chi square value was computed 
with df = 1. KHI, Karachi sample; CHIN, Chinese of Han ancestry; CAUC, Caucasian of Northern and Western 
European ancestry, GUJ, Gujrati Indians in Houston Texas; AFR, African of Yoruba Nigerian ancestry.
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effects of this observation should be explored, especially for warfarin and phenytoin due to their narrow thera-
peutic index.
CYP2C19. While CYP2C19*2 leads to complete loss-of-function, CYP2C19*17 is associated with 
gain-of-function. Several widely used drugs such as the antiplatelet clopidogrel36, antifungal voriconazole37, and 
the antidepressant citalopram38 are metabolized by CYP2C19. Because of problems in efficacy and pharmacoki-
netics, the USFDA and other such agencies include pharmacogenetic information in some drug labels to optimize 
the use of drugs, such as clopidogrel. Our data shows that only 27% of the Pakistani population had normal phe-
notype (CYP2C19*1/*1). Thus, further studies are required to elucidate the pharmacogenetics in this population, 
especially regarding drugs used in acute emergencies, such as clopidogrel in acute coronary syndrome.
CYP2D6. This highly polymorphic enzyme is involved in the metabolism of more than 20% of drugs. Notable 
examples include the antidepressant paroxetine38, SERM tamoxifen39, antipsychotic clozapine40, adrenocep-
tor antagonists metoprolol and carvedilol among others41. Our data shows that the minor allele frequency was 
approximately 30%, whereas, 26% population had genotypes associated with some degree of functional loss.
ALDH3A1. Aldehyde dehydrogenases are phase-1 metabolizing enzymes which exist as different isoen-
zymes. Our focus was ALDH3A1 which is involved in a broad spectrum of physiological activities, including the 
protection of oral and respiratory tract mucosa from damage caused by cigarette smoke12, food and air pollut-
ants42, and ionizing radiation43. Additionally, it is involved in preventing ultraviolet light induced corneal dam-
age44, detoxification of 4-HNE (4-hydroxynonenal; a by-product of lipid peroxidation)9, generation of NO from 
organic nitrates36, metabolism of oxazophorines like cyclophosphamide8, and synthesis of Coenzyme Q11. Thus, 
ALDH3A1 takes part in drug metabolism and reduction of oxidative stress. We had previously shown that the 
prevalence of ALDH3A1 (985C > G) variant allele shows significant differences among various ethnicities in 
HapMap database and was much more prevalent (62.5%) in Pakistani breast cancer patients with 40% homozy-
gous for variant allele19. In this study, we have shown that it is similarly prevalent in the healthy population 
(67% variant allele; 42% homozygous variant genotype). So far however, there is lack of concrete evidence that 
non-functional ALDH3A1 is associated with increased disease risk.
GSTA1. Glutathione S-transferase A1 is the most abundant form of GSTs in human liver, kidney, adrenal 
gland and testis, where they appear to scavenge electrophiles and reduce oxidative stress45. It also appears to reg-
ulate other functions. For example, a recent in vitro study suggested that GSTA1 may facilitate nicotine-induced 
lung cancer metastasis46. Another study suggested its role in metabolism of anticancer drug busulfan47. We had 
previously reported that loss of GSTA1 is a major determinant of neutropenia among breast cancer patients 
receiving standard dose FAC (5-fluorouracil, doxorubicin, cyclophosphamide) chemotherapy8. Our current 
results also show that prevalence of variant allele is lower (30.5%) in the Pakistani population as compared to 
others in HapMap database (range: 58.4–89.5%) though in absolute terms it is still high.
Figure 1. Variant allele frequencies (percent) of drug metabolizing enzymes and ABC transporters in healthy 
Pakistanis as compared to the HapMap Database (http://www.ncbi.nlm.nih.gov/SNP/). KHI, Karachi Pakistan 
(current study); CHIN, Chinese of Han ancestry; CAUC, Caucasians of Northern and Western European 
ancestry; AFR, African of Yoruba Nigerian ancestry; GUJ, Gujrati Indian ancestry living in Houston, Texas, 
USA. Green highlighted row shows current study sample and yellow shaded areas show significant difference 
from KHI samples computed through chi-square or Fisher exact test. The missing values indicate absence of 
data in HapMap database for that particular SNV.
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GSTM1. Glutathione S-transferase M1 is another GST believed to eliminate oxidative intermediates in the 
alimentary tract as posed by dietary toxins. The role of GSTM1 null genotype as a susceptibility factor for various 
carcinoma is conflicting, although a large meta-analysis comprising 198 studies revealed an association of lung 
cancer to GSTM1 null genotype48. Other studies have suggested that GSTM1 null genotype is associated with 
pathogenesis of chronic obstructive pulmonary disease49, or increased likelihood of toxicity of cyclophospha-
mide50 and oxaliplatin51. Our results show a high prevalence of putative “at risk” null genotype (59%). A recent 
study from Pakistan observed elevated levels of carcinogenic 1-hydroxypyrene in GSTM1 null carriers52, making 
further molecular epidemiological studies necessary in the Pakistani population.
ABCB1. The ATP-binding cassette transporter B1, also called MDR1 (multi-drug resistance protein 1) or P-gp 
(permeability glycoprotein), is a membrane transporter located at many interfaces in the body53. It actively trans-
ports various xenobiotics and toxins across the cell membranes and has been implicated in antineoplastic drug 
resistance54. Certain drugs, such as amiodarone, clarithromycin, omeprazole, and calcium channel blockers, can 
inhibit this protein leading to drug-drug interactions55. Our results show a prevalence of 54–65% variant alleles of 
ABCB1 (1236C > T, 2677G > T/A, 3435C > T; rs1128503, rs2032582, rs1045642 respectively). These frequencies 
are not significantly different from most populations except African.
ABCC2. ATP-binding cassette transporter C2, also called MRP2 (multidrug resistance-associated protein 2) 
or CMOAT (Canalicular Multispecific Organic Anion Transporter), is an active efflux transporter identified at 
apical or biliary canalicular surfaces of hepatocytes and in the kidney. There is mounting evidence that by pro-
moting efflux in target cells this protein is involved in the resistance to several drugs, such as antiepileptics56, 
antiretroviral drugs57, antineoplastic drugs58, and statins among others59. Conversely, its decreased function may 
lead to increased drug toxicity. Our data (Tables 2 and 3) suggests that a substantial proportion of the population 
has diplotypes with some degree of functional deficit where the prevalence of variant alleles ranges from 15–37%. 
Thus, the effects of this finding should be explored in terms of drug efficacy and toxicity.
In conclusion, this study showed that in our sample compared with other ethnic populations, there was a 
generally higher prevalence (p < 0.05) of variant alleles of ALDH3A1, CYP1A1*2A, CYP2B6*4, CYP2B6*6, 
CYP2C19*2, CYP3A5*3, ABCB1 2677G > T/A and ABCC2 1249G > A. Further, GSTM1 null genotype also had 
higher frequency. There is a lower prevalence of variant alleles of GSTA1, and ABCC2 3972C > T as compared to 
other ethnicities. As mentioned above, these results are not significantly different from our previously reported 
Pakistani female breast cancer patients19, thus suggesting real differences between our sample and other ethnici-
ties in HapMap database, namely African, Caucasian, and Chinese. Hence, further research in other population 
cohorts within the country and the region would be beneficial for a more complete understanding of the pharma-
cogenetic landscape in a region which is underrepresented in genetic studies. This is an important step forward in 
achieving widespread and cost-effective implementation of personalized medicine in the community60.
Methods
The study was conducted at Jinnah Medical and Dental College (JMDC), Karachi, Pakistan from July 2013 to 
December 2015 after approval by The Ethics Committee of Jinnah Medical & Dental College, in accordance with 
relevant guidelines. The study cohort included students and employees of JMDC who were invited to be volun-
teers and gave written informed consent.
Saliva was the source of genomic DNA. The saliva samples were collected and stored in Oragene® DNA col-
lection kits (DNA Genotek Inc. Canada) according to manufacturer’s recommendations. DNA was extracted 
through the proprietary extraction kit provided with collection kits. The extracted DNA was air-shipped to 
the Institute of Experimental and Clinical Pharmacology, Christian-Albrechts University, Kiel, Germany for 
genotyping.
For primers and experimental method details, see Supplementary Tables 1 and 2. Briefly, genotyping was 
performed by restriction fragment length polymorphism (RFLP) for CYP1A1 SNVs rs1048943 (g.3798C > T, 
*2A and *2B), rs1799814 (g.2454A > G, *2B) and rs4646903 (g.2452C > A, *4); for CYP2B6 SNVs rs2279343 
(c785A > G, *4), rs3211371 (c.1459C > T, *5) and rs3745274 (c.516G > T, *6); for CYP2C9 SNVs rs1799853 
(430C > T, *2) and rs1057910 (1075A > C, *3); for CYP2C19*2 SNV rs4244285 (681G > A); for CYP2D6 
SNVs rs5030655 (g.1707delT, *6), rs3892097 (g.1846C> T, *4), rs35742686 (g.2549delA, *3), rs5030656 
(g.2615-g.2617delAAG, *9 and rs1065852 (g.100C > T), *10); and for CYP3A5 SNV rs776746 (g.6986G > A, *3). 
The CYP2D6 deletion (*5) and gene duplication could not be determined in the DNA retrieved from saliva spec-
imen. All homozygous variant genotypes detected through RFLP were repeated to ensure accuracy.
A PSQ HS 96 (Qiagen, Hilden, Germany) was used for pyrosequencing (PSQ) SNVs for GSTA1 −69C > T 
and −52G > A (rs3957357 and rs3957356 respectively; representing GSTA1*A and GSTA1*B haplotype); for 
ALDH3A1 (985C > G; rs2228100), and for CYP3A4 (15389C > T; rs35599367. Novel PSQ methods were 
established for CYP2C19*17, ABCB1 SNVs (rs1128503, g.1236C > T; rs2032582 g.2677G > T/A; rs1045642 
g.3435C > T), and for ABCC2 (rs717620 −g.24C > T, rs2273697 g.1249G > A, rs3740066 g.3972C > T). For all 
the PCR reactions, a GeneAmp PCR 9700 Thermocycler (Applied Biosystems, Darmstadt, Germany) was used.
The data was analysed using SPSS® version 19.0 software (IBM, Ehningen, Germany). The results were entered 
as frequencies, and percentage and 95% confidence interval (proportions) was calculated. All genotype frequen-
cies were tested and found to be within Hardy-Weinberg equilibrium. Allele frequency data was compared 
through χ2 or Fisher’s Exact test where applicable. A p-value < 0.05 was considered significant.
Data Availability
The authors undertake that materials, data and associated protocols would be made available to readers.
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